H. Bachelez

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Kenneth B. Gordon, Bruce Strober, Mark Lebwohl et al. · The Lancet · 2018 · 662 citations

Medicine, Clinical Sciences, Pharmacotherapy +11

Trial of Spesolimab for Generalized Pustular Psoriasis

H. Bachelez, Siew Eng Choon, Slaheddine Marrakchi et al. · New England Journal of Medicine · 2021 · 337 citations · Full text

Medicine, Dermatology, Pharmacotherapy +15

Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study

Satveer K. Mahil, Nick Dand, K.J. Mason et al. · Journal of Allergy and Clinical Immunology · 2020 · 160 citations · Full text

Medicine, Dermatology, Health Sciences +12

Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study

Ulrich Mrowietz, H. Bachelez, A. David Burden et al. · Journal of the American Academy of Dermatology · 2019 · 142 citations · Full text

Medicine, Dermatology, Pharmacotherapy +13

Pustular Psoriasis: The Dawn of a New Era

H. Bachelez · Acta Dermato Venereologica · 2020 · 136 citations · Full text

Life Sciences, Dermatology, Genetics +17